Kyverna Therapeutics, Inc.
KYTX
$3.78
-$0.03-0.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.08M | -44.64M | -37.49M | -34.49M | -28.80M |
| Total Depreciation and Amortization | 515.00K | 501.00K | 563.00K | 558.00K | 530.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.39M | 1.40M | -169.00K | 1.19M | -310.00K |
| Change in Net Operating Assets | 8.23M | -2.18M | 34.00K | 5.25M | 4.41M |
| Cash from Operations | -31.95M | -44.92M | -37.06M | -27.49M | -24.18M |
| Capital Expenditure | -4.00K | -- | -532.00K | -102.00K | -1.03M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.17M | 5.58M | 29.75M | 778.00K | -66.89M |
| Cash from Investing | 29.17M | 5.58M | 29.22M | 676.00K | -67.92M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -262.00K | -341.00K | -247.00K | -242.00K | -236.00K |
| Issuance of Common Stock | 0.00 | 3.00K | 32.00K | 90.00K | 73.00K |
| Repurchase of Common Stock | -51.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -336.00K | -76.00K | 0.00 | 0.00 | -406.00K |
| Cash from Financing | -649.00K | -414.00K | -215.00K | -152.00K | -569.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.43M | -39.75M | -8.05M | -26.97M | -92.67M |